RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC

Aix, S.Novello, S.Garon, E.Nakagawa, K.Nadal, E.Moro-Sibilot, D.Alonso Garcia, M.Fabre, E.Frimodt-Moller, B.Zimmermann, A.Visseren-Grul, C.Reck, M.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/27251enEU/US subsetEGFR-mutation positive NSCLCRamucirumabRELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLCconference outputopen access10.1016/j.jtho.2019.08.13171556-1380http://www.jto.org/article/S1556086419320003/pdf492162203232